Clinical Trial Update: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who have had at least two prior treatments, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Triple-negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING